This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

Krystal Biotech KRYS reported first-quarter 2026 earnings per share (EPS) of $1.83, which surpassed the Zacks Consensus Estimate of $1.45. The reported EPS was up from $1.20 in the year-ago quarter.

Ascentage Pharma reported 2024 sales of $134.3M, up 342% YoY, driven by a $100M option payment from Takeda under an exclusive agreement. JP Morgan initiated Ascentage Pharma with an Overweight rating ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals, including Johnson & ...

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine. Click here to read an ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Reported Standalone quarterly numbers for Windlas Biotech are: Net Sales at Rs 238.50 crore in March 2026 up 17.66% from Rs.

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...